Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
359 Developing human placental CD34-derived natural killer cells with high affinity and cleavage resistant CD16 and secreted IL-15 (CYNK-201) for cancer immunotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.